B
BridgeBio Pharma, Inc. (BBIO)
NMS – Real Time Price. Currency in USD
70.24
+0.55 (0.79%)
At close: Jun 26, 2026, 4:00 PM EDT
70.91
+0.67 (0.95%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
70.24
+0.55 (0.79%)
At close: Jun 26, 2026, 4:00 PM EDT
70.91
+0.67 (0.95%)
After-hours: Jun 26, 2026, 7:59 PM EDT
No Data
There are no news for this stock.
Total debt $3.4B significantly exceeds cash reserves ($880.4M), raising financial stability concerns
Total current assets $1.2B exceed Total current liabilities $816.4M, highlighting excellent liquidity
Debt-to-equity ratio (-1.5) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-2.0x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$197.3M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.52 | 6.05 | 8.0 | |
| Quick ratio | 1.48 | 5.63 | 7.0 | |
| Debt to Equity | N/A | 0.30 | 1.0 | |
| Debt to Assets | 2.47 | 1.04 | 1.0 | |
| Interest coverage | -2.01 | -16.91 | 1.0 | |
| Weighted average score | 3.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 78M | 9M | 222M | 502M | 580M |
| Gross Profit | 70M | 3M | 214M | 478M | 549M |
| Operating Income | -468M | -599M | -577M | -502M | -504M |
| Net Income | -481M | -643M | -536M | -725M | -722M |
| EBITDA | -462M | -593M | -571M | -497M | -499M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 99.75 | 38.43 | 10 |
| Next quarter | 111.56 | 50.24 | 10 |
| Current year | 92.97 | 42.66 | 10 |
| Next year | 64.53 | 124.92 | 10 |
| Weighted average score | 10 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 26.16 | 14.94 | 16 | -249.57 | 7.0 |
| Y/Y | 66.78 | 2.02 | 4.55 | 0.95 | 4.8 |
| 3y average | 774.51 | -17.41 | -8.43 | -2.83 | 3.3 |
| 5y average | 616.01 | -12.62 | -2.29 | -3.46 | 3.3 |
| Weighted average score | 4.6 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | Narrow | 2.0 |
| Intangible assets | Medium | 5.0 |
| Switching costs | Narrow | 2.0 |
| Network effect | None | 1.0 |
| Economies of scale | Narrow | 3.0 |
| Weighted average score | 2.6 | |